BayOConnect 2026: Regulatory Framework Determines Success in Biotech.

From June 30 to July 1, 2026, Munich will become a hub for the biotech community: At this year’s BayOConnect, the organizers will bring together founders, researchers, investors, and established partners at the Design Offices München Macherei. At the heart of the event is a fundamental question: How can young biotech companies secure long-term market access and preserve the value of their scientific breakthroughs?

This is precisely where Martina Schneider (Chief of Staff at CSL Innovation GmbH and co-founder of LOVEDIS) and Lena Pauli-Tzschirner (Principal Consultant at Entourage GmbH) come in with their exclusive live joint interview. Their goal at the conference is to show founders and investors that market access and regulatory compliance are not merely downstream bureaucratic obligations, but rather the strongest drivers of a company’s actual valuation.

Four Key Topics in the Spotlight for BayOConnect Partners

The biotech ecosystem thrives on collaboration and strategic foresight. During the conference, the two experts will discuss how startups can navigate the typical pitfalls of the early stages of development:

• Company Value & Investor Appeal (Valuation): In BayOConnect’s investor matching process, financial viability is the most important factor. A coherent, well-planned repayment plan gives startups the confidence they need when raising venture capital.
• Incorporate Reimbursement and HTA Requirements Early: Many developers focus primarily on the technology in the early stages. This dual interview illustrates why taking payer evidence and HTA (Health Technology Assessment) into account early on drastically reduces the risk of failure at the market threshold.
• TechBio, AI & Regulatory Sandboxes: This year’s conference focuses heavily on digitalization in the biotech sector. Discussions will center on how AI can be brought into practice more quickly during the R&D phase through forward-looking regulatory frameworks (such as the IHI-BRIDGE project).
• What startup ecosystems need: Capital alone is not enough. Biotech startups require direct access to modern R&D infrastructure and incubators (such as the CSL Incubator in Marburg), as well as experienced mentors to help with operational implementation.

Come meet us in person at Design Offices München Macherei

Take advantage of the networking opportunities at BayOConnect 2026 to engage in direct discussions. In addition to the live double interview, Co-Founder & Managing Director Moritz Haucke and Lena Pauli-Tzschirner will be representing Entourage GmbH at the event. Talk to us about market access roadmaps, regulatory issues, or collaboration models at the intersection of Entourage and SmartStep Consulting.